A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Alanine
Disease-Free Survival
Endometrial Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Receptor, Fibroblast Growth Factor, Type 2
Triazines
Vascular Endothelial Growth Factor A

authors with profiles

Doris M Benbrook
Robert S Mannel